 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 06/09/2008 | | | | Nymox Starts Phase 3 Program for NX-1207
topic: R&D: BPH (enlarged prostate) Treatments
June 9, 2008: Nymox announced today that, following recent communications with the U.S. Food and Drug Administration (FDA), the Company is commencing its Phase 3 development program for NX-1207, Nymox's investigational product for the treatment of benign prostatic hyperplasia (BPH). The Company will begin Phase 3 clinical trials in the U.S. later this year to support a New Drug Application (NDA) to the FDA. |
| 05/30/2008 | | | | Nymox Announces New Clinical Trial Data Presentation on BPH Drug at Upcoming American Urological Association Meeting
topic: R&D: BPH (enlarged prostate) Treatments
May 30, 2008: Nymox today announced that new clinical trial data concerning the safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Northeastern Section of the American Urological Association Meeting on September 18. |
| 05/28/2008 | | | | Nymox Reports Significant Long-Term Improvement in BPH Symptoms After NX-1207 Treatment in New Multi-Center U.S. Study
topic: R&D: BPH (enlarged prostate) Treatments
May 28, 2008: Nymox today announced significant long-term improvement in symptoms of benign prostatic hyperplasia (BPH) in men treated with the Company’s investigational drug NX-1207 in a newly completed clinical study. |
| 05/15/2008 | | | | Independent Clinical Investigators to Present Data on Nymox BPH Drug at American Urological Association Meeting in Chicago September 25
topic: R&D: BPH (enlarged prostate) Treatments
May 15, 2008: Nymox today announced that new clinical trial data concerning the safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the North Central Section of the American Urological Association Meeting in Chicago September 25. |
| 05/14/2008 | | | | Nymox Reports First Quarter 2008 Financial Results
topic: Financial
May 14, 2008: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the first quarter of 2008. |
| 05/07/2008 | | | | Nymox Reports New Large Cohort U.S. 3 Year Follow-Up Clinical Study of NX-1207 for BPH Near Completion
topic: R&D: BPH (enlarged prostate) Treatments
May 7, 2008: Nymox announced today that a large new 3 year follow-up study of NX-1207 for benign prostatic hyperplasia is near completion. The study evaluated symptomatic progress of over one hundred subjects involved in the Company’s Phase 2 U.S. clinical trial initiated in 2005. Individuals in the study were assessed 3 years after NX-1207 treatment for symptomatic improvement, treatment outcomes, and durability of efficacy. The Company anticipates the reporting of final results and statistical analysis for the study within the next 2-3 weeks. |
| 05/06/2008 | | | | Brief Exposure to Second-Hand Smoke Bad for Health According to New Study
topic: Tobacco Exposure Tests
May 6, 2008: Nymox offers TobacAlert™ Urine, an easy-to-use test for second-hand smoke exposure that requires no special equipment or training and can be used for at home or at the workplace. Even a brief exposure to second-hand smoke may hurt human blood vessels according to a new study published in the most recent issue of the Journal of the American College of Cardiology. |
| 04/30/2008 | | | | Nymox Announces New Positive Results at 54 Months in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
April 30, 2008: Nymox today announced new positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company’s two Phase 1-2 studies initiated in 2003. Overall, 75% of the patients in the new outcome study treated with NX-1207 reported no current drug treatment for their BPH and had a mean improvement of 11.1 points in AUA Symptom Score. In addition, 38% of the patients reported no other approved treatments at any time for their BPH since their original treatment with NX-1207, with a mean improvement of 9.8 points. |
| 04/22/2008 | | | | New Peer Review Publications Support Nymox Saliva Smoking Test
topic: Tobacco Exposure Tests
April 22, 2008: Nymox announced today the publication of new independent studies finding that the Company's NicAlert™ Saliva product provides an accurate, convenient and cost-effective way to verify self-reported smoking status with broad potential applications both in the clinic and in large research trials and surveys. |
| 04/17/2008 | | | | Nymox Announces Clinical Study Presentation on BPH Drug at American Urological Association Meeting
topic: R&D: BPH (enlarged prostate) Treatments
April 17, 2008: Nymox announced that new clinical trial data concerning the safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the South Central Section of the American Urological Association Meeting in San Diego in September. |
|